Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
BUZZ-Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million Updates
** Shares of drugmaker Biohaven BHVN.N rise 5.4% to $15.15
** Biohaven enters a partnership with South Korean drug maker SK Biopharmaceuticals 326030.KS worth up to $795 million to license and commercialize a new epilepsy drug platform
** SK Biopharmaceuticals gains exclusive global rights to Biohaven's lead epilepsy drug candidate, opakalim
** Opakalim is in mid-to-late stage trial testing for focal epilepsy, and trial results are expected in H2 2026
** Biohaven to use SK's established epilepsy development and sales network to bring opakalim to patients globally
** Biohaven's deal with SK Biopharmaceuticals for Kv7 and opakalim rights resolves a key near-term capital overhang- William Blair
** Biohaven will certainly now generate significantly more near-to-mid-term cash from the launch, than it would have if it launched itself- TD Cowen
** Including session's moves, BHVN up ~32% YTD
(Reporting by Kamal Choudhury and Sneha S K in Bengaluru)
Recent news on SK Biopharmaceuticals
See all newsBrief: Sk Biopharmaceuticals Co Signs Licensing-In Contract With 1St Biotherapeutics
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker